{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:06:56Z","timestamp":1756339616175,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,11,8]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor receptors, has become a widely used treatment for various types of cancer, including metastatic colorectal cancer. However, while the benefits of bevacizumab in improving survival outcomes have been well-documented, it is important to consider the potential adverse effects associated with this therapy. We report a case of a male patient in his 50s with a history of metastatic colorectal cancer who began a regimen of bevacizumab in combination with chemotherapy. After several months of treatment, the patient began to experience rhinorrhoea and nasal crusting. Physical examination revealed a perforation of the nasal septum. While nasal septum perforation (NSP) is a known adverse effect of bevacizumab therapy, it is an uncommon occurrence, with only a few reported cases in the literature. Although no further extension of the NSP has been observed during the follow-up period, the treatment with bevacizumab was discontinued.<\/jats:p>","DOI":"10.1136\/bcr-2024-263121","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T21:45:56Z","timestamp":1733435156000},"page":"e263121","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Nasal septum perforation induced by bevacizumab therapy for metastatic colorectal cancer"],"prefix":"10.1136","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8117-5528","authenticated-orcid":false,"given":"Paulo","family":"Pina","sequence":"first","affiliation":[{"name":"Otorhinolaryngology, Gaia e Espinho Local Health Unit, Vila Nova de Gaia, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Gaia e Espinho Local Health Unit, Vila Nova de Gaia, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edite","family":"Coimbra","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, Gaia e Espinho Local Health Unit, Vila Nova de Gaia, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Branquinho","sequence":"additional","affiliation":[{"name":"Otorhinolaryngology, IPO Coimbra, Coimbra, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"2025082712512610000_17.12.e263121.1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605828"},{"key":"2025082712512610000_17.12.e263121.2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2010.537692"},{"key":"2025082712512610000_17.12.e263121.3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-1-85"},{"key":"2025082712512610000_17.12.e263121.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"2025082712512610000_17.12.e263121.5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01690"},{"key":"2025082712512610000_17.12.e263121.6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/14737140.2016.1246187","article-title":"The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer","volume":"17","author":"Minion","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025082712512610000_17.12.e263121.7","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1517\/14740338.2014.960388","article-title":"An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab","volume":"13","author":"D\u2019Amico","year":"2014","journal-title":"Expert Opin Drug Saf"},{"key":"2025082712512610000_17.12.e263121.8","unstructured":"BC Cancer Drug Manual . Bevacizumab bc cancer drug manual. 2022. Available: http:\/\/www.bccancer.bc.ca\/drug-database-site\/Drug Index\/Bevacizumab_monograph.pdf"},{"key":"2025082712512610000_17.12.e263121.9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.amjoto.2017.01.018","article-title":"Nasal septal perforation secondary to systemic bevacizumab","volume":"38","author":"Geltzeiler","year":"2017","journal-title":"Am J Otolaryngol"},{"key":"2025082712512610000_17.12.e263121.10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/tbj.12913","article-title":"Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer","volume":"23","author":"Rodriguez","year":"2017","journal-title":"Breast J"},{"key":"2025082712512610000_17.12.e263121.11","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/jog.14589","article-title":"A case of nasal septal perforation caused by bevacizumab for advanced cervical cancer","volume":"47","author":"Taira","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"key":"2025082712512610000_17.12.e263121.12","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp451"},{"key":"2025082712512610000_17.12.e263121.13","doi-asserted-by":"publisher","DOI":"10.1097\/MLG.0b013e31817c4296"},{"key":"2025082712512610000_17.12.e263121.14","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-10-1070"},{"key":"2025082712512610000_17.12.e263121.15","doi-asserted-by":"crossref","DOI":"10.1007\/s11882-018-0754-1","article-title":"Nasoseptal Perforation: from Etiology to Treatment","volume":"18","author":"Pereira","year":"2018","journal-title":"Curr Allergy Asthma Rep"},{"key":"2025082712512610000_17.12.e263121.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01105.x"},{"key":"2025082712512610000_17.12.e263121.17","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1111\/ajco.12320","article-title":"Aflibercept-related nasal septum perforation","volume":"13","author":"Alkan","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025082712512610000_17.12.e263121.18","article-title":"Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report","volume":"14","author":"Benitez Fuentes","year":"2022","journal-title":"Cureus"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-263121","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:51:32Z","timestamp":1756324292000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-263121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,5]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bcr-2024-263121"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-263121","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}